These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14653352)

  • 21. Self-designing two-stage trials to minimize expected costs.
    Thach CT; Fisher LD
    Biometrics; 2002 Jun; 58(2):432-8. PubMed ID: 12071417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approximately optimal designs for phase II clinical studies.
    Stallard N
    J Biopharm Stat; 1998 Jul; 8(3):469-87. PubMed ID: 9741860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach.
    Berry DA; Ho CH
    Biometrics; 1988 Mar; 44(1):219-27. PubMed ID: 3358990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dynamic programming approach to the efficient design of clinical trials.
    Claxton K; Thompson KM
    J Health Econ; 2001 Sep; 20(5):797-822. PubMed ID: 11558649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
    Mayo MS; Gajewski BJ
    Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A bayesian approach to the design of phase II clinical trials.
    Sylvester RJ
    Biometrics; 1988 Sep; 44(3):823-36. PubMed ID: 3203131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Bayesian principle: can we adapt?
    Berry DA
    Stroke; 2005 Jul; 36(7):1623-4. PubMed ID: 15947273
    [No Abstract]   [Full Text] [Related]  

  • 31. Approaches for optimal sequential decision analysis in clinical trials.
    Carlin BP; Kadane JB; Gelfand AE
    Biometrics; 1998 Sep; 54(3):964-75. PubMed ID: 9750245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian assessment of sample size for clinical trials of cost-effectiveness.
    O'Hagan A; Stevens JW
    Med Decis Making; 2001; 21(3):219-30. PubMed ID: 11386629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian ranking of sites for engineering safety improvements: decision parameter, treatability concept, statistical criterion, and spatial dependence.
    Miaou SP; Song JJ
    Accid Anal Prev; 2005 Jul; 37(4):699-720. PubMed ID: 15949462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Bayesian with group sequential methods for monitoring clinical trials.
    Armitage P
    Control Clin Trials; 1991 Apr; 12(2):345-50. PubMed ID: 1645645
    [No Abstract]   [Full Text] [Related]  

  • 35. Bayesian sample size determination for prevalence and diagnostic test studies in the absence of a gold standard test.
    Dendukuri N; Rahme E; Bélisle P; Joseph L
    Biometrics; 2004 Jun; 60(2):388-97. PubMed ID: 15180664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian predictive approach for inference about proportions.
    Lecoutre B; Derzko G; Grouin JM
    Stat Med; 1995 May 15-30; 14(9-10):1057-63; discussion 1064. PubMed ID: 7569500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian sample-size determination for inference on two binomial populations with no gold standard classifier.
    Stamey JD; Seaman JW; Young DM
    Stat Med; 2005 Oct; 24(19):2963-76. PubMed ID: 16007574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Bayesian noninferiority approach to evaluation of bridging studies.
    Liu JP; Hsueh H; Hsiao CF
    J Biopharm Stat; 2004 May; 14(2):291-300. PubMed ID: 15206527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The utility of prior information and stratification for parameter estimation with two screening tests but no gold standard.
    Gustafson P
    Stat Med; 2005 Apr; 24(8):1203-17. PubMed ID: 15558709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploratory thoughts on clinical trials with utilities.
    Tan SB; Smith AF
    Stat Med; 1998 Dec; 17(23):2771-91. PubMed ID: 9881422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.